You are here



The study conducted by the Joan XXIII University Hospital in Tarragona was selected over six top-notch projects from Belgium, the Netherlands, Germany and Italy.


The new facilities will help maintain the good positioning the Vall d’Hebron Research Institute has reached in recent years on an international level.


The new therapy consists of extracting, modifying and reintroducing cells from the immune system to prevent the destruction of beta cells.


Enric Esmatjes: "Now there must be a change in mentality on behalf of both professionals and the administration in terms of quantifying resources assigned to this"


Global experts, including a significant number of researchers from Vall d’Hebron, will meet on 30 and 31 May to seek out more effective treatments.


The HAVCR-1/KIM1 protein predicts and prognosticates different types of kidney cancer, including clear cell (ccRCC), in the early stages.


Intrahepatic cholangiocarcinoma was until now an orphan cancer from a molecular point of view. Some 400 cases are diagnosed in Spain each year.


The Europe-wide trial is using an eye drop developed by a Catalan company to prevent retinal neurodegeneration for the first time.


Pelvic-floor therapy is used to treat urinary incontinence, which affects one in four Spanish women over 65.


The space, with more than 5,000 square meters and 200 researchers, will be devoted to translational research of excellence to compete on an international level.